MicroTex

MicroTex is a Research and Partnership Hub developing advanced technologies for intra-target microdosing, which allows scientists to test multiple drugs at very small doses directly to the affected tissue.

This provides early insight into how drugs act, helping to inform decisions and advance the drug development pipeline and allows for scientists to focus resources on the most promising treatments.  

Initially, MicroTex is focusing on two target areas, inflammation in the distal lung, and microbial keratitis, corneal infections of the eye and a leading cause of blindness worldwide.  

The aim is to develop technologies which can help identify and develop drugs more effectively and efficiently, helping to bring new treatment to patients all over the world.  

Based at The University of Edinburgh’s Institute for Regeneration and Repair, within the Baillie Gifford Pandemic Science Hub, MicroTex is a collaboration involving engineers, scientists and clinicians from The University of Edinburgh, Heriot-Watt University and University of Bath.  

Funded by the Engineering and Physical Science Research Council (EPSRC)

What is MicroTex?

MicroTex is a Research and Partnership Hub developing advanced technologies for intra-target microdosing, which allows scientists to test multiple drugs at very small doses directly to the affected tissue.

Based at The University of Edinburgh’s Institute for Regeneration and Repair, within the Baillie Gifford Pandemic Science Hub, MicroTex is a collaboration involving engineers, scientists and clinicians from The University of Edinburgh, Heriot-Watt University and University of Bath.

Every  day  around  the  world, millions  of  people  are  being infected  by  infection  and inflammation  in  many  parts  of  the  human  body. And  antimicrobial  resistance  is  one of  the  biggest  challenges  to  modern  medicine. What  if  we  could  find  a  new  way,  a  faster, better  way  to  develop  drugs, to  take  them  to patient  groups  around  the  world? Microtech  is  developing  advanced  technologies that  enable  a  new  approach called  intra  target  microdosing, in  which  scientists  test tiny  amounts  of  novel  medicines  on tiny  areas  of  tissue  directly at  the  site  of  disease, then  measure  the  effect. By  measuring  what  happens at  the  target  tissue, researchers  can  make  better  decisions  earlier and  focus  resources  on the  most  promising  treatments. So  Microtech  is  all  about  that and  focusing  on  two  disease  areas. One  is  antimicroial  resistance information  in  the  lungs, and  the  other  one  is  in  coneourtitis, and  meanness  bindssness  in the  front  of  the  eye. Infections  affecting  the  cornea, which  is  the  clear  layer at  the  front  of  the  eye, are  an  ophthalmic  emergency  and a  leading  cause  of  blindness  worldwide. These  infections  are  treated  with  eye  drops, but  tears  and  blinking wash  away  most  of  the  medicine before  it  can  be  absorbed, reducing  its  effectiveness. Micro  techs  are  developing a  tiny  patch  that  delivers  medicine directly  to  the  cornea  while measuring  how  the  tissue responds  to  the  treatment. This  will  help  drugs  to  get to  where  they  are  most  needed to  actually  treat  the  infection  and  can  help researchers  understand  much  earlier if  the  treatments  are  working. So  some  lung  infections are  investigated  with  bronchoscopy, where  we  use  a  bronchoscope, a  small,  thin  camera  tube  that's  inserted down  into  the  deep  parts  of the  lung  so  we  can  take  samples. However,  the  lung  is  very  complex, and  the  anatomy  means  that it's  very  difficult  for  us  to reliably  get  into these  deep  parts  of  the  lung. At  Micro  techs,  we're developing  a  bronchoscopy  system  that  uses robotics  and  artificial  intelligence so  we  can  more  reliably  and accurately  get  into  those  deep  dark  areas  of the  lung  and  go  back  there time  and  time  again  to  the  same  exact  spot. This  will  help  us  understand  how our  treatments  are  affecting that  part  of  the  lung  and ultimately  will  hopefully  help  our  patients. Research  is  always  stronger when  it's  driven  by  clinical  needs  and the  live  experience  of  patients  who  are experiencing  lung  and  eye  infections. In  micro  techs,  we  are  constantly making  decisions  about  risks and  benefits  to  patients. These  decisions  are  not  purely  technical. They  also  require  an  understanding  of what  matters  to  patients  and  society. So  by  involving  patients and  the  public  in  everything  we  do, we  ensure  that  the  research  that  we develop  is  not  only  scientifically  rigorous, but  also  socially  relevant  and  meaningful. Micro  Techs  is a  multi  million  pound  collaboration involving  engineers, scientists  and  clinicians  at the  University  of  Edinburgh, Marriott  Wart  University, and  the  University  of  Bath. It  is  developing  advanced  tools to  make  new  drug  development  faster, smarter,  and  more  precise. So  why  does  it  matter?  It  means we  can  find  new  effective  treatments  earlier, faster,  reduce  costly  failures, improve  decision  making  to bring  these  therapies  to  patients. It  will  also  reduce  but remove  the  need  for  animal  testing.